Immunic Inc. has secured up to $400 million in a private placement to fund late-stage clinical trials for vidofludimus calcium in multiple sclerosis and prepare for its commercial launch. CEO Dr. Daniel Vitt described the financing as transformative, noting that $200 million has already been received. The funds will support the completion of the Phase 3 ENSURE program in relapsing MS and allow the company to initiate a Phase 3 study in primary progressive MS.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic Inc. has secured up to $400 million in a private placement to fund late-stage clinical trials for vidofludimus calcium in multiple sclerosis and prepare for its commercial launch. CEO Dr. Daniel Vitt described the financing as transformative, noting that $200 million has already been received. The funds will support the completion of the Phase 3 ENSURE program in relapsing MS and allow the company to initiate a Phase 3 study in primary progressive MS.